Health & Fit Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
Monkeypox antivirals are extremely hard to access. Clinical trials could make it easier
Patients who have been able to obtain the drug say it’s helped improve their symptoms, but getting access was an extremely difficult process.Having contracted monkeypox this month, the lanky, bespectacled 29-year-old project manager had been suffering from what he called “the most severe pain of my life” for over a week before he finally was able to obtain a course of antivirals — a treatment he hoped would soon clear up his lesions and alleviate his suffering.
Artelo Biosciencs ARTL were up 46% on Aug 16, during market hours, after the company announced positive initial data from a pre-clinical study for one of its novel inhibitors to fatty acid binding protein 5 (FABP5) in anxiety-related disorders.
The clinical-stage pharma company announced the publication of its pre-clinical data exhibiting the potential efficacy of one of its FABP inhibitor from the company’s FABP inhibitor platform in reducing anxiety behaviors in a part of the brain important in anxiety.
The data also highlights the potential of modulating the FABP5 system as a target to develop novel anxiolytics.
Here’s What Happens When You Stop Wearing a Bra
Going braless is a personal choice. Here the pros and the cons according to experts. The post Here’s What Happens When You Stop Wearing a Bra appeared first on The Healthy.
Additionally, the pre-clinical data demonstrated that the CB2 receptor, involved in the control of fear and anxiety in the brain, is now capable of being modulated by the FABP5 inhibitor.
Per the company, these results from the study can help in developing novel anxiety-inhibiting pharmacotherapies.
Shares of Artelo have plunged 18.3% so far this year compared with the industry’s decline of 16%.
Image Source: Zacks Investment Research
The company’s lead FABP5 inhibitor, ART26.12, is currently being developed as a potential treatment for chemotherapy-induced peripheral neuropathy, prostate cancer and breast cancer, pain, and post-traumatic stress disorder (PTSD).
“God, no, not another case”: COVID-related stillbirths didn’t have to happen
Many avoided the COVID-19 vaccine during pregnancy, unwittingly increasing their chances of a stillbirth Ultrasound pregnancy examination of a young woman in a Medical Clinic during COVID-19 outbreak Getty Images
In June, the company reported positive results from a pre-clinical study of its patented products candidate ART26.12, exhibiting that the candidate could prevent and treat chemotherapy-induced pain in patients without any sedating effects.
Artelo is also developing a cannabinoid agonist G protein-coupled receptor (GPCR) targeting synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer in a phase Ib/IIa study.
Zacks Rank and Stocks to Consider
Artelo Biosciences currently carries a Zacks Rank #3 (Hold)
Some better-ranked stocks in the same sector include Immunovant IMVT, Inozyme Pharma INZYand Sutro Biopharma STRO, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
This week, Sanofi SNY discontinued the development of its oral SERD, amcenestrant while Novartis’ NVS lung cancer candidate, canakinumab missed the primary endpoint in a phase III study. The FDA granted priority review status to AstraZeneca AZN and Merck’s MRK Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancerand accepted GSK’s GSK regulatory application seeking approval for momelotinib for treating myelofibrosis.
Immunovant’s loss per share estimates for 2022 have narrowed from $1.66 to $1.64 in the past 30 days. The same for 2023 has narrowed from $1.94 to $1.75 in the same time frame. SGEN has returned 11.8% in the year-to-date period.
Earnings of Immunovant missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average negative earnings surprise for IMVT is 8.97%.
Inozyme Pharma’s loss estimates for 2022 have narrowed to $2.08 from a loss of $2.10 in the past 30 days. The loss estimates for 2023 also narrowed down from $2.01 per share to $1.95 per share in the same time frame.
INZY surpassed earnings in three of the trailing four quarters, missing the same in one. The average earnings surprise for Inozyme is 6.65%.
Sutro Biopharma’s loss per share estimates for 2022 have narrowed from $3.27 to $2.36 in the past 30 days. The same for 2023 has narrowed from $3.43 to $2.91 in the same time frame.
Earnings of Sutro missed estimates in two of the trailing four quarters, beat the same on one occasion and were in line with the estimate on the other remaining occasion. The average negative earnings surprise for STRO is 1.13%.
This team of doctors reveals how to avoid a massive pitfall in making new drugs .
Identifying and addressing the barriers to enrolling in research that patients face can increase participation and lead to better patient care.Clinical trial participants are predominantly white. Despite Black and Hispanic people respectively making up 12 percent and 16 percent of the U.S. population in 2011, together, they made up only 6 percent of clinical trial participants overall that year.